欧康维视：产品OT-703在乐城的真实世界研究已完成195例患者入组

Core Viewpoint - Ocular Therapeutix announced the completion of patient enrollment for its product OT-703 in a real-world study in Hainan Province, China, focusing on the treatment of diabetic macular edema (DME) [1] Group 1: Product Information - OT-703 is an injectable, non-biodegradable fluocinolone acetonide intravitreal implant designed to treat diabetic macular edema (DME) [1] - The implant can continuously release micro-doses of the non-proprietary corticosteroid fluocinolone acetonide (FAc) for up to 36 months [1] Group 2: Study Details - The real-world study has successfully enrolled 195 patients [1]